Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) have been given a consensus rating of “Moderate Buy” by the nine brokerages that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $17.44.

ATEC has been the topic of several recent analyst reports. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Alphatec in a research note on Thursday, August 1st. Morgan Stanley downgraded shares of Alphatec from an “overweight” rating to an “equal weight” rating in a research note on Thursday, August 1st. Canaccord Genuity Group reissued a “buy” rating and set a $20.00 price objective on shares of Alphatec in a research note on Friday. Barclays started coverage on shares of Alphatec in a research note on Monday, July 8th. They set an “overweight” rating and a $19.00 price objective on the stock. Finally, Needham & Company LLC cut their price target on shares of Alphatec from $23.00 to $13.00 and set a “buy” rating on the stock in a research note on Thursday, August 22nd.

Alphatec Stock Up 0.7 %

Shares of NASDAQ ATEC opened at $6.90 on Monday. Alphatec has a 12-month low of $5.57 and a 12-month high of $17.34. The company has a market capitalization of $965.20 million, a PE ratio of -4.63 and a beta of 1.40. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.22 and a quick ratio of 1.49. The firm’s 50-day moving average is $8.69 and its two-hundred day moving average is $11.23.

Alphatec (NASDAQ:ATEC) last announced its quarterly earnings data on Wednesday, July 31st. The medical technology company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.03). The firm had revenue of $145.57 million for the quarter, compared to analysts’ expectations of $144.55 million. Alphatec had a negative net margin of 33.48% and a negative return on equity of 816.57%. The business’s quarterly revenue was up 24.5% on a year-over-year basis. During the same period in the previous year, the company posted ($0.43) EPS. Equities analysts anticipate that Alphatec will post -1.04 EPS for the current fiscal year.

Insider Buying and Selling

In other Alphatec news, General Counsel Tyson Eliot Marshall sold 50,232 shares of the firm’s stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $10.88, for a total transaction of $546,524.16. Following the transaction, the general counsel now owns 245,638 shares of the company’s stock, valued at approximately $2,672,541.44. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other Alphatec news, General Counsel Tyson Eliot Marshall sold 50,232 shares of the stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $10.88, for a total transaction of $546,524.16. Following the completion of the transaction, the general counsel now directly owns 245,638 shares of the company’s stock, valued at approximately $2,672,541.44. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director David M. Demski acquired 50,000 shares of the company’s stock in a transaction dated Wednesday, August 21st. The stock was purchased at an average cost of $5.67 per share, for a total transaction of $283,500.00. Following the purchase, the director now directly owns 288,441 shares in the company, valued at approximately $1,635,460.47. The disclosure for this purchase can be found here. Corporate insiders own 22.80% of the company’s stock.

Hedge Funds Weigh In On Alphatec

Hedge funds have recently made changes to their positions in the business. Comerica Bank boosted its holdings in Alphatec by 64.8% during the first quarter. Comerica Bank now owns 6,443 shares of the medical technology company’s stock worth $89,000 after buying an additional 2,534 shares in the last quarter. Van ECK Associates Corp grew its holdings in shares of Alphatec by 11.8% in the 2nd quarter. Van ECK Associates Corp now owns 12,275 shares of the medical technology company’s stock worth $128,000 after acquiring an additional 1,300 shares during the last quarter. Tidemark LLC acquired a new stake in shares of Alphatec during the fourth quarter worth $137,000. EntryPoint Capital LLC purchased a new stake in shares of Alphatec during the first quarter valued at $141,000. Finally, Amalgamated Bank boosted its position in shares of Alphatec by 7.3% in the 4th quarter. Amalgamated Bank now owns 9,720 shares of the medical technology company’s stock valued at $147,000 after purchasing an additional 660 shares during the period. Institutional investors and hedge funds own 66.35% of the company’s stock.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.